Ann: Trading Halt, page-98

Yes a lot has happened in the last 3 months.

The entire bio-tech small cap sector globally has been burned as the stupid mkt woke up to the US Fed led bubble, for one and two we have a war in Europe that has dented global mkt sentiment further.

Meanwhile, OCC has announced TGA approval for CelGro Nerve (Remplir), increasing US sales in CelGro Bone (Straite), near completion of a US distributor deal on Straite, manufacturing expansion of Straite production, the forthcoming completion of its other randomised controlled study of ATI and further data pending in the DePuy ATI study.

The progression with OCC is all far slower than we hoped, but its clearly there. This company has a suite of promising products that are steadily gaining approval in the US, Europe and Australia in an area of business decimated by COVID. Its ridiculously under-valued and ripe for the picking by big Pharma. I've made some good money overseas sitting on such partnership/take-over prospects - but for these forums am wrong....until I am right. Its a very cheap call option.